Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors
Clinical trial NCT05291052 · UNKNOWN
Trial details
- NCT number
- NCT05291052
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-14
- Primary completion
- 2023-03-30
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.